The global antifungal drugs market size reached USD 15.6 Billion in 2024. Looking forward, the publisher expects the market to reach USD 20.6 Billion by 2033, exhibiting a growth rate (CAGR) of 2.99% during 2025-2033. The rising prevalence of fungal infections, ongoing advancement in antifungal drug development, improved diagnostic technologies, and expanding geriatric population, are primarily driving the market's growth.
According to the antifungal drugs market outlook, azoles are effective against a broad spectrum of fungi, including Candida species, Aspergillus species, and dermatophytes. This broad activity makes them suitable for treating a wide range of fungal infections. Moreover, the emergence of drug-resistant fungal strains, such as resistant Candida and Aspergillus species, has created a need for effective antifungal treatments. New azoles and those with improved pharmacological profiles are being developed to address these resistance issues. Azoles are often used in combination with other antifungal agents to enhance efficacy against resistant strains and reduce the risk of resistance development.
According to the antifungal drugs market overview, candidiasis is one of the most common fungal infections, particularly in immunocompromised patients, including those with HIV/AIDS, cancer, diabetes, or undergoing organ transplants. The high prevalence of this infection drives demand for effective antifungal treatments. Moreover, candidiasis is also a common healthcare-associated infection, particularly in hospitalized patients with central venous catheters or those undergoing invasive procedures. This drives the need for potent antifungal therapies in hospital settings.
According to the antifungal drugs market statistics, the incidence of fungal infections such as candidiasis, aspergillosis, and cryptococcosis is increasing, partly due to the growing number of immunocompromised patients. For instance, according to an article published by the U.S. Centers for Disease Control and Prevention, an estimated 25,000 cases of candidemia occur in the United States each year. This rise in infection rates drives demand for effective antifungal treatments. Moreover, the incidence of fungal infections such as candidiasis, aspergillosis, and cryptococcosis is increasing, partly due to the growing number of immunocompromised patients. This rise in infection rates drives demand for effective antifungal treatments. Furthermore, innovations in antifungal drug development, including the introduction of new classes of antifungals such as newer azoles and echinocandins, enhance treatment options and drive market growth.
2.What is the expected growth rate of the global antifungal drugs market during 2025-2033?
3.What has been the impact of COVID-19 on the global antifungal drugs market?
4.What are the key factors driving the global antifungal drugs market?
5.What is the breakup of the global antifungal drugs market based on the drug class?
6.What is the breakup of the global antifungal drugs market based on the indication?
7.What are the key regions in the global antifungal drugs market?
8.Who are the key players/companies in the global antifungal drugs market?
Antifungal Drugs Market Trends:
Rising Prevalence of Fungal Infections
The frequency of fungal infections, such as candidiasis, aspergillosis, and dermatophyte infections, is on the rise. For instance, according to an article published by Global Action for Fungal Infections, each year, more than 80 million individuals are at high risk of dying from a fungal disease or losing their vision. Every year, approximately 6 million patients contract life-threatening fungal infections, with nearly 3.75 million dying as a result. This increase in cases drives higher demand for antifungal treatments to manage and treat these infections effectively.Emergence of Chronic Diseases
The increasing number of individuals with chronic conditions, such as diabetes and cancer, heightens the risk of fungal infections. For instance, according to the World Health Organization (WHO), in 2022, there were nearly 20 million new cancer diagnoses and 9.7 million fatalities. About 1 in 5 people develop cancer in their lifetime, and about 1 in 9 men and 1 in 12 women die from it. Similarly, according to an article published by the American Cancer Society, in 2024, nearly 2,001,000 new cancer cases and approximately 611,700 cancer deaths were expected in the United States. Patients undergoing cancer treatments or those with chronic illnesses often have weakened immune systems, making them more susceptible to infections. These factors further positively influence the antifungal drugs market forecast.Technological Advancements
Advances in diagnostic tools, such as rapid molecular tests and improved imaging techniques, enable earlier and more accurate diagnosis of fungal infections. This leads to increased use of antifungal treatments. For instance, in February 2024, HaystackAnalytics, based at IIT-Bombay, and NIMS Medicity, located in Neyyattinkara, collaborated to introduce 'infexnTM', a genomics test for identifying infectious disorders. The 'infexnTM' is a cutting-edge targeted next-generation sequencing test designed to detect any fungal infection, thereby boosting the antifungal drugs market revenue.Global Antifungal Drugs Industry Segmentation:
The publisher provides an analysis of the key trends in each segment of the global antifungal drugs market report, along with forecasts at the global, regional, and country levels from 2025-2033. Our report has categorized the market based on drug class and indication.Breakup by Drug Class:
- Azoles
- Voriconazole (Vfend)
- Posaconazole (Noxafil)
- Clotrimazole (Canesten)
- Isavuconazole (CRESEMBA)
- Others
- Echinocandins
- Caspofungin (Cancidas)
- Micafungin (Mycamine/ Funguard)
- Others
- Polyenes
- Amphotericin (AmBisome)
- Others
- Allylamines
- Terbinafine (Lamisil)
- Others
- Others
Azoles currently hold the largest market share
The report has provided a detailed breakup and analysis of the antifungal drugs market based on the drug class. This includes azoles (voriconazole (vfend), posaconazole (noxafil), clotrimazole (canesten), isavuconazole (CRESEMBA), and others), echinocandins (caspofungin (cancidas), micafungin (mycamine/ funguard), and others), polyenes (amphotericin (ambisome) and others), and allylamines (terbinafine (lamisil) and others), and others. According to the report, azoles currently hold the largest market share.According to the antifungal drugs market outlook, azoles are effective against a broad spectrum of fungi, including Candida species, Aspergillus species, and dermatophytes. This broad activity makes them suitable for treating a wide range of fungal infections. Moreover, the emergence of drug-resistant fungal strains, such as resistant Candida and Aspergillus species, has created a need for effective antifungal treatments. New azoles and those with improved pharmacological profiles are being developed to address these resistance issues. Azoles are often used in combination with other antifungal agents to enhance efficacy against resistant strains and reduce the risk of resistance development.
Breakup by Indication:
- Dermatophytosis
- Aspergillosis
- Candidiasis
- Invasive Candidiasis
- Vulvovaginal Candidiasis (VVC)
- Mouth/Throat/Esophageal Candidiasis
- Others
- Others
Currently, candidiasis exhibits a clear dominance in the market
The report has provided a detailed breakup and analysis of the antifungal drugs market based on the indication. This includes dermatophytosis, aspergillosis, candidiasis (invasive candidiasis, vulvovaginal candidiasis (VVC), mouth/throat/esophageal candidiasis, and others), and others. According to the report, candidiasis exhibits a clear dominance in the market.According to the antifungal drugs market overview, candidiasis is one of the most common fungal infections, particularly in immunocompromised patients, including those with HIV/AIDS, cancer, diabetes, or undergoing organ transplants. The high prevalence of this infection drives demand for effective antifungal treatments. Moreover, candidiasis is also a common healthcare-associated infection, particularly in hospitalized patients with central venous catheters or those undergoing invasive procedures. This drives the need for potent antifungal therapies in hospital settings.
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America currently dominates the global market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America currently dominates the global market.According to the antifungal drugs market statistics, the incidence of fungal infections such as candidiasis, aspergillosis, and cryptococcosis is increasing, partly due to the growing number of immunocompromised patients. For instance, according to an article published by the U.S. Centers for Disease Control and Prevention, an estimated 25,000 cases of candidemia occur in the United States each year. This rise in infection rates drives demand for effective antifungal treatments. Moreover, the incidence of fungal infections such as candidiasis, aspergillosis, and cryptococcosis is increasing, partly due to the growing number of immunocompromised patients. This rise in infection rates drives demand for effective antifungal treatments. Furthermore, innovations in antifungal drug development, including the introduction of new classes of antifungals such as newer azoles and echinocandins, enhance treatment options and drive market growth.
Competitive Landscape:
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:
- Abbott Laboratories
- Arcadia Consumer Healthcare Inc.
- Astellas Pharma Inc.
- Bayer AG
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Scynexis Inc.
Key Questions Answered in This Report
1.What was the size of the global antifungal drugs market in 2024?2.What is the expected growth rate of the global antifungal drugs market during 2025-2033?
3.What has been the impact of COVID-19 on the global antifungal drugs market?
4.What are the key factors driving the global antifungal drugs market?
5.What is the breakup of the global antifungal drugs market based on the drug class?
6.What is the breakup of the global antifungal drugs market based on the indication?
7.What are the key regions in the global antifungal drugs market?
8.Who are the key players/companies in the global antifungal drugs market?
Table of Contents
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Antifungal Drugs Market
6 Market Breakup by Drug Class
7 Market Breakup by Indication
8 Market Breakup by Region
9 SWOT Analysis
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Arcadia Consumer Healthcare Inc.
- Astellas Pharma Inc.
- Bayer AG
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Scynexis Inc.
